Only in Titles

Search results for: Human Amylin ELISA Kit

paperclip

#33312210   2020/08/28 To Up

The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers .

Irregularities of angiogenesis may participate in the pathogenesis of diabetes complications. Pramlintide is an amylin analogue administered for the treatment of type 1 and type 2 diabetes. The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs).
Leila Safaeian, Golnaz Vaseghi, Mina Mirian, Mehdi Dehghani Firoozabadi

2548 related Products with: The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers .

8 Sample Kit100ul 6 ml Ready-to-use 50ug2 Pieces/Box0.05 mg Aff Pur100.00 ul32-50 Sample Kit100ug4 Membranes/Box

Related Pathways

paperclip

#14605801   2003/11/07 To Up

Amylin fasting plasma levels are decreased in patients with osteoporosis.

Amylin is a polypeptide hormone produced in pancreatic beta-cells that belongs to the family of calcitonin gene-related peptides. There is a 20% sequence homology between amylin and calcitonin and 44% homology with calcitonin gene-related peptide. Amylin and its fragments stimulate the proliferation of osteoblasts, inhibit bone resorption, and increase bone density and the amount of bone mass. We measured amylin total and unreduced amylin fasting plasma levels in patients with osteoporosis ( n=28; 3 men, 25 women; mean age 65 years), type 2 diabetes mellitus ( n=10; 5 men, 5 women; 64 years), and in the control group ( n=24; 11 men, 13 women; 53 years) using an ELISA kit with immunofluorescent detection (Linco). Amylin total plasma levels in patients with osteoporosis were 3.33+/-0.46 pmol/l (mean+/-SEM), in patients with type 2 diabetes 6.29+/-1.47 pmol/l (mean+/-SEM), and in the control group 8.48+/-3.12 pmol/l (mean+/-SEM). Mean plasma levels were lower in patients with osteoporosis than in patients with type 2 diabetes and in the control group. Unreduced amylin plasma levels in patients with osteoporosis ( n=28) were 2.51+/-0.87 pmol/l (mean+/-SEM), in patients with type 2 diabetes ( n=10) 4.15+/-0.95 pmol/l (mean+/-SEM) and in the control group ( n=5) 13.50+/-3.94 pmol/l (mean+/-SEM). Plasma levels were significantly lower in patients with osteoporosis than in patients with type 2 diabetes ( P<0.01) and in the control group ( P<0.001). Amylin plasma levels are decreased in patients with osteoporosis. Amylin deficiency in these patients may contribute to the development of osteoporosis. Amylin should be investigated in relation to the pharmacological treatment of osteoporosis.
J Bronský, R Průsa

2243 related Products with: Amylin fasting plasma levels are decreased in patients with osteoporosis.

100 μg

Related Pathways